Articles from Amprion

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced publication of new peer-reviewed research in npj Parkinson's Disease, a Nature Portfolio journal, demonstrating that its skin-based α-synuclein seed amplification assay (skin SAA) can differentiate multiple system atrophy (MSA) from neuronal synuclein diseases (NSD), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), representing an important step toward expanding access to seed amplification-based biomarker testing for neurodegenerative disease.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Prema Cognition, a leader in digital precision memory assessments, today announced a collaboration to explore a more comprehensive approach to identifying and evaluating individuals at risk for neurodegenerative disease.

A new innovation in the detection of MSA pathology is here.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a strategic licensing collaboration with MLM Medical Labs, a global central and specialty laboratory with operations in Germany. Through the agreement, Amprion will license its proprietary seed amplification assay (SAA) methodology, the technology that powers its SAAmplify®-αSYN test, to enable α-synuclein testing for biopharma-sponsored clinical trials in Europe. The collaboration expands access to pathology-based biomarker testing, helping accelerate neurodegenerative disease research and therapeutic development across Europe.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a series of strategic milestones that underscore the company’s accelerating growth, expanding international footprint, and continued commitment to advancing earlier and more accurate diagnosis of neurodegenerative diseases.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic’s network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer’s Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, announces a groundbreaking paper in The Lancet Neurology. The study demonstrates the ability of the synuclein seed amplification assay (synSAA) to differentiate between Type 1 and Type 2 synuclein seeds, addressing the critical need for accurate diagnosis of multiple system atrophy (MSA). This fatal synucleinopathy is often misdiagnosed as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), or other related disorders, delaying proper care and access to clinical trials.

Amprion, a global leader advancing diagnoses of neurodegenerative disorders, is closing out 2024 with several prestigious awards. Its novel assay, SAAmplify™-ɑSYN, won ‘Clinical Diagnostics Solution of the Year’ through the Biotech Breakthrough Awards Program. The Michael J. Fox Foundation (MJFF) also awarded Amprion’s co-founder, Dr. Claudio Soto, with ‘The Robert A. Pritzker Prize for Leadership in Parkinson's Research.’

Amprion, a global leader advancing diagnoses of neurodegenerative disorders, today announced the successful initial $6 million close of a $15 million Series B financing. The round was led by Formation Venture Engineering (FVE) with participation by Eli Lilly and Company and Amprion’s Series A investors. It will expand Amprion’s commercial reach and enable increased R&D investment to further Amprion’s mission to revolutionize brain disease diagnosis.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, commends the U.S. Food & Drug Administration’s (FDA) move to issue a Letter of Support (LoS) recommending the use of the alpha-synuclein (α-syn) seed amplification assay (synSAA) for research and clinical trials.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, is launching a new line of cerebrospinal fluid (CSF) biomarker panels: SAAmplify. Physicians and their patients will now have access to the most comprehensive set of biomarkers available to aid in the diagnosis of Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with the Lewy body variant.